Literature DB >> 23040316

Distinct structural alterations independently contributing to working memory deficits and symptomatology in paranoid schizophrenia.

Kathrin C Zierhut1, Anna Schulte-Kemna, Jörn Kaufmann, Johann Steiner, Bernhard Bogerts, Kolja Schiltz.   

Abstract

Schizophrenia is considered a brain disease with a quite heterogeneous clinical presentation. Studies in schizophrenia have yielded a wide array of correlations between structural and functional brain changes and clinical and cognitive symptoms. Reductions of grey matter volume (GMV) in the prefrontal and temporal cortex have been described which are crucial for the development of positive and negative symptoms and impaired working memory (WM). Associations between GMV reduction and positive and negative symptoms as well as WM impairment were assessed in schizophrenia patients (symptomatology in 34, WM in 26) and compared to healthy controls (36 total, WM in 26). GMV was determined by voxel-based morphometry and its relation to positive and negative symptoms as well as WM performance was assessed. In schizophrenia patients, reductions of GMV were evident in anterior cingulate cortex, ventrolateral prefrontal cortex (VLPFC), superior temporal cortex, and insula. GMV reductions in the superior temporal gyrus (STG) were associated with positive symptom severity as well as WM impairment. Furthermore, the absolute GMV of VLPFC was strongly related to negative symptoms. These predicted WM performance as well as processing speed. The present results support the assumption of two distinct pathomechanisms responsible for impaired WM in schizophrenia: (1) GMV reductions in the VLPFC predict the severity of negative symptoms. Increased negative symptoms in turn are associated with a slowing down of processing speed and predict an impaired WM. (2) GMV reductions in the temporal and mediofrontal cortex are involved in the development of positive symptoms and impair WM performance, too.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040316     DOI: 10.1016/j.cortex.2012.08.027

Source DB:  PubMed          Journal:  Cortex        ISSN: 0010-9452            Impact factor:   4.027


  6 in total

1.  Decreased expression of cortactin in the schizophrenia brain.

Authors:  Hriday P Bhambhvani; Micah Simmons; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuroreport       Date:  2016-02-10       Impact factor: 1.837

2.  Delineation of hippocampal subregions using T1-weighted magnetic resonance images at 3 Tesla.

Authors:  Kathryn Rhindress; Toshikazu Ikuta; Robin Wellington; Anil K Malhotra; Philip R Szeszko
Journal:  Brain Struct Funct       Date:  2014-08-01       Impact factor: 3.270

3.  N-Glycosylation of GABAA receptor subunits is altered in Schizophrenia.

Authors:  Toni Marie Mueller; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-08-06       Impact factor: 7.853

Review 4.  Molecular underpinnings of prefrontal cortex development in rodents provide insights into the etiology of neurodevelopmental disorders.

Authors:  D Schubert; G J M Martens; S M Kolk
Journal:  Mol Psychiatry       Date:  2014-12-02       Impact factor: 15.992

5.  Extensive gray matter volume reduction in treatment-resistant schizophrenia.

Authors:  Valerie M Anderson; Meghan E Goldstein; Robert R Kydd; Bruce R Russell
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

6.  Long-term effects of maternal deprivation on cholinergic system in rat brain.

Authors:  Branka Marković; Nevena V Radonjić; Milan Aksić; Branislav Filipović; Nataša Petronijević
Journal:  Biomed Res Int       Date:  2014-03-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.